Abacavir Sulfate

證據等級: L5

預測適應症: 0 個

ABACAVIR SULFATE: Repurposing Readiness Assessment — Insufficient Data to Complete Full Evaluation

One-Sentence Summary

Abacavir Sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) widely used in HIV-1 treatment regimens. The current Evidence Pack contains no TxGNN-predicted new indications, and critical data elements — including mechanism of action, package insert warnings, and product-level registration details — are missing. With 6 active registrations confirmed in Malaysia but no repurposing candidates generated, this evaluation cannot proceed beyond a preliminary readiness assessment.

Quick Overview

Item	Content
Original Indication	Not retrieved (license details unavailable)
Predicted New Indication	No prediction available
TxGNN Prediction Score	Not available
Evidence Level	N/A
Malaysia Market Status	✓ Marketed
Number of Registrations	6
Recommended Decision	Hold

Why Is This Prediction Reasonable?

No repurposing candidates were returned by the TxGNN model in this evaluation run. Without a predicted new indication, mechanistic bridging analysis between an original and a target disease cannot be performed.

Furthermore, mechanism of action (MOA) data is listed as a data gap (DG002), which means even a manual mechanistic rationale cannot be constructed at this stage. Abacavir’s pharmacological class is known from the literature to be NRTI, but a formal MOA profile from DrugBank has not been retrieved and should not be substituted with assumptions.

Until the prediction pipeline is re-run with a complete drug entry (including a valid DrugBank ID) and MOA data is retrieved, this section will remain incomplete.

Malaysia Market Information

Six registrations are confirmed by the NPRA query (query ID 1, status: success), but product-level details — including authorization numbers, product names, dosage forms, and approved indication text — were not populated in the current Evidence Pack. The table below reflects what is available.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	Details not retrieved; 6 registrations confirmed via NPRA

Action required: Re-query NPRA with full license retrieval to populate product details before proceeding to clinical review.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings and contraindications are listed as blocking data gaps (DG001). A known class-specific concern for abacavir is HLA-B*5701-associated hypersensitivity syndrome — this should be explicitly captured when package insert data is retrieved and must be addressed in any prospective repurposing protocol.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack lacks predicted indications, a valid DrugBank ID, MOA data, and package insert safety information — the minimum inputs required for a repurposing evaluation. Proceeding without these would produce an unreliable result.

To proceed, the following is needed:

TxGNN prediction pipeline: Re-run with a resolved DrugBank ID for Abacavir Sulfate to generate repurposing candidates
DrugBank ID resolution: Map “ABACAVIR SULFATE” to its DrugBank entry (expected: DB01048) via the DrugBank API
MOA data retrieval (DG002): Query DrugBank for mechanism of action, pharmacodynamics, and drug targets
Package insert retrieval (DG001 — Blocking): Download and parse the NPRA/TFDA package insert PDF to extract warnings, contraindications, and special population guidance
NPRA license details: Re-query NPRA to populate authorization numbers, product names, dosage forms, and approved indication text for all 6 registrations
HLA-B*5701 screening policy: Confirm whether Malaysia’s current clinical guidelines mandate pre-treatment genotyping, as this is a material safety guardrail for any repurposing study design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.